|
EDITORIAL BOARD
 Maurie Markman, MD Senior Vice President of Clinical Affairs and National Director for Medical Oncology, Cancer Treatment Centers of America, Philadelphia |
Arecently reported Phase III trial that examined the utility of intermittent versus continuous androgen deprivation therapy for metastatic prostate cancer provides the background for this commentary. Before proceeding, I’d like to make clear that the intent of this all-too-brief discussion is not to